SIGMAR1
Sigma non-opioid intracellular receptor 1
As of the edition of 20 October 2026, SIGMAR1 (sigma non-opioid intracellular receptor 1, UniProt Q99720) has 8 drugs tested at it and 12 companies on the list, 2 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q99720
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 5
- Disease areas
- Nervous system; Mental health; Inherited and neonatal; Infections; Lungs and airways; Nutrition and metabolism; Cancer; Chemically induced
- Registered trials of its drugs
- 177
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 2 |
| Went quiet | 2 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Dextromethorphan | Marketed | Phase 4 | none listed |
| Fenfluramine | Marketed | Phase 4 | Ends 2036 |
| AXS-05 | Active | Phase 4 | none listed |
| Blarcamesine | Active | Phase 3 | none listed |
| Pentazocine | Marketed | Phase 4 | none listed |
| SA4503 | Went quiet | Phase 2 | none listed |
| Carbetapentane | Marketed | Phase 1 | none listed |
| SR31747A | Went quiet | Phase 2 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 3 |
| Engaged | 4 |
| Undetermined | 3 |
| Total on the list | 12 |
The other 9 companies at SIGMAR1
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at SIGMAR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.